Studies have shown that elevated FOXO1 expression in the liver may lead to an increase in FBG in mice (Van Berendoncks et al., 2015), while the inhibition of FOXO1 expression in the liver may delay the progression of diabetes and fatty liver (Herder et al., 2016). This evidence concerns the gene FOXO1 and Hepatic steatosis.